Filter by: patients
What is Fampridine (4-AP immediate release)?

Fampridine, also known as by its chemical name 4-aminopyridine or 4-AP, a potassium channel blocker that is used to improve walking in patients with Multiple Sclerosis. Fampridine is an immediate release formulation of 4-AP that is compounded by pharmacist.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Improve mobility 17 8 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_cant_tell
Weakness in legs 6 2 Efficacy_moderate Efficacy_none
MS (Multiple Sclerosis) 5 1 Efficacy_cant_tell
Walking problems 4 1 Efficacy_moderate
Other 3 2 Efficacy_major
Stiffness/Spasticity 3 1 Efficacy_slight

See all 33 patients currently taking Fampridine (4-AP immediate release)

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
1
Mild
4
None
10

Reported Dosages

Frequently reported dosages based on patients currently taking Fampridine (4-AP immediate release). See all 13 dosages

  2 other daily 5 mg daily 7.5 mg daily 10 mcg daily 10 mg daily 15 mg daily 20 mg daily 22.5 mg daily 30 mg daily 40 mg daily
  2 Number of Patients: 2 2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2 5 Number of Patients: 5 5 Number of Patients: 5 9 Number of Patients: 9 1 Number of Patients: 1 2 Number of Patients: 2 3 Number of Patients: 3  

Reported Stop Reasons

Why Patients Stopped Taking Fampridine (4-AP immediate release) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other 7   Other: 47%
Did not seem to work 4   Did not seem to work: 27%
Course of treatment ended 3   Course of treatment ended: 20%

See all 14 patients who’ve stopped taking Fampridine (4-AP immediate release)

Currently Taking Fampridine (4-AP immediate release)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0

Stopped Taking Fampridine (4-AP immediate release)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Fampridine (4-AP immediate release)

Always
11 73%
Usually
1 7%
Sometimes
1 7%
Never
2 13%

Burden

Difficulty being on treatment

Burden of Fampridine (4-AP immediate release)

Very
0 0%
Somewhat
1 7%
A little
0 0%
Not at all
14 93%

Cost

Paid out of pocket

Cost of Fampridine (4-AP immediate release)

$200+
0 0%
$100-199
1 8%
$50-99
4 31%
$25-49
4 31%
< $25
4 31%

Report created on May 28, 2012.